Search

everythinglearnresearchcommunity

for

Search:↓

Combining a GnRH agonist with a low-dose oral contraceptive is more effective and safer for treating hirsutism than using either alone.

Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.

Metreleptin treatment significantly improved metabolic health in a boy with congenital generalized lipodystrophy.

Leuprolide plus estrogen is more effective than oral contraceptives for reducing hirsutism.

Linagliptin may cause hair loss and skin blisters.

A woman got unwanted hair growth on her face from using bimatoprost eyedrops for glaucoma.

Tislelizumab can cause cutaneous lupus erythematosus.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

Linagliptin slows down premature aging in certain mice.

Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.

Leuprolide effectively reduces hair growth in hirsute women at higher doses.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Juläine injections safely improve hair regrowth in men and women with pattern hair loss.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Ac-GFFY-IGF peptide is a promising, safe, and effective treatment for hair loss, better than current options.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

Two men experienced hair regrowth while being treated with immune globulin for other health issues, but there were also side effects.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

Upadacitinib effectively treats pyoderma gangrenosum.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.

Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.